Plain-English translation of NCT07465224 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is an early-stage research study testing a medication called to see if it can help your body use insulin better. The study will give you either the medication or a placebo (a dummy pill that looks identical), and researchers will measure how your body responds. This is a randomized, double-blind study, meaning neither you nor the researchers will know which you received until the study ends.
Type 2 diabetes happens when your body struggles to use insulin effectively, which leads to high blood sugar. This medication is being tested to see if it can improve insulin sensitivity, potentially offering a new treatment option for people with type 2 diabetes.
You likely qualify if…
You likely don't qualify if…
You will receive a single dose of either the medication or placebo as part of this study. Researchers will then measure your insulin sensitivity through blood tests and other assessments to see how the treatment affects your body's ability to use insulin. The study involves a relatively small group of 24 participants total, so you would be part of focused research with careful monitoring.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Alnylam Pharmaceuticals
Enrollment target
~24 participants
Started
January 2026
Primary completion
May 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alnylam Clinical Trial Information Line
Alnylam Pharmaceuticals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.